Open AccessNilotinib-induced perforating folliculitis: Two cases
Author(s) -
Neerja Saraswat,
Ajay Chopra,
Debdeep Mitra,
Krishna Talukdar
Publication year - 2018
Publication title -
international journal of trichology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.494
H-Index - 22
eISSN - 0974-9241
pISSN - 0974-7753
DOI - 10.4103/ijt.ijt_85_17
Subject(s) - nilotinib , medicine , myeloid leukemia , adverse effect , tyrosine kinase inhibitor , drug , dermatology , folliculitis , chemotherapy , limiting , pharmacology , imatinib , cancer , engineering , mechanical engineering
Cutaneous adverse effects of chemotherapy are widely known but underreported. A significant advancement is made in the field of oncology with the advent of new classes of drug being added to the existing classes at a fast pace. Most of these cutaneous adverse effects are self-limiting and subsides on suspending the drug either temporarily or permanently. Some of these effects are merely overlooked by the patients and the treating physician hence goes un-noticed. Nilotinib is a newer second-generation tyrosine-kinase inhibitor approved for the management of chronic myeloid leukemia. This drug is rapidly establishing itself as afirst-line therapy for chronic myeloid leukemia. Like other chemotherapeutic agents, a wide array of cutaneous adverse effects is noted with this drug. We report two cases of perforating folliculitis induced by nilotinib.